Current Potential of Pantoprazole in Treatment and Prevention of Gastrointestinal Diseases
https://doi.org/10.22416/1382-4376-2021-31-1-47-53
Abstract
Aim. An outline of the current potential of pantoprazole in treatment and prevention of upper gastrointestinal diseases.
Key points. Pantoprazole is widely applied in gastroesophageal reflux, peptic ulcer disease, Zollinger—Ellison syndrome and for Helicobacter pylori eradication. It minimally inhibits the CYP2C19 isoenzyme involved in the metabolism of many drugs. Pharmacokinetics of pantoprazole conditions a weaker drug interaction compared to other proton pump inhibitors (PPIs), which enables its use for gastrointestinal bleeding prevention in patients receiving dual antiplatelet therapy. The new coronaviral pandemic of COVID-19 urges the selection of PPIs that minimise the drug interference, such as pantoprazole, in therapy and prevention of acid-related upper gastrointestinal diseases. Pantoprazole has a good tolerance and low side effect rate.
Conclusion. Pantoprazole is considered among optimal PPIs for efficacy, safety and adherence on the basis of clinical trials for treatment and prevention of gastrointestinal diseases, systematic reviews and meta-analyses.
Keywords
pantoprazole,
peptic ulcer,
gastroesophageal reflux,
gastrointestinal bleeding Conflict of interest: the publication was supported by the KRKA company
Supporting agencies: The publication was supported by the KRKA company.
About the Authors
A. A. Sheptulin
Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Arkadiy A. Sheptulin — Dr. Sci (Med.), Professor, Department of Internal Diseases Propedeutics, Gastroenterology and Hepatology, Sechenov First Moscow State Medical University (Sechenov University).
119435, Moscow, Pogodinskaya str., 1/1.
S. S. Kardasheva
Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Svetlana S. Kardasheva — Cand. Sci (Med.), Associate Professor, Department of Internal Diseases Propedeutics, Gastroenterology and Hepatology, Sechenov First Moscow State Medical University (Sechenov University).
119435, Moscow, Pogodinskaya str., 1/1.
A. A. Kurbatova
Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Anastasya A. Kurbatova — Cand. Sci (Med.), Assistant, Department of Internal Diseases Propedeutics, Gastroenterology and Hepatology, Sechenov First Moscow State Medical University (Sechenov University).
119435, Moscow, Pogodinskaya str., 1/1.
References
1. Sachs G., Shin J.M. The basis of differentiation of PPIs. Drugs today. 2004;40 (suppl.A):9-14. PMID: 15190382
2. Vacyshyn B.R., Thompson A.B.R. The clinical importance of proton pump inhibitor pharmacokinetics. Digestion. 2002;66(2):67-78. DOI: 10.1159/000065588
3. Jonaitis P., Jonaitis L., Kupcinskas J. Role of genetic polymorphisms of cytochrome P450 2C19 in pantoprazole metabolism and pantoprazole-based Helicobacter pylori eradication regimens. Curr. Drug Metab. 2020;21(11):830-7. DOI: 10.2174/1389200221666200514081442
4. Wedemeyer R.-S., Blume H. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf. 2014;37(4):201-11. DOI: 10.1007/s40264-014-0144-0
5. Angiolillo D.J., Gibson C.M., Cheng S., Ollier C., Nicolas O., Bergougnan L., et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther. 2011;89(1):65-74. DOI: 10.1038/clpt.2010.219
6. Choi Y.J. Kim N., Jang I.J., Cho J.Y., Nam R.H., Park J.H., et al. Pantoprazole does not reduce the antiplatelet effect of clopidogrel: A randomized controlled trial in Korea. Gut Liver. 2017;11(4):504-11. DOI: 10.5009/gnl16352
7. Matheus S., Reid A., Tian C., Cai Q. An update on the use of pantoprazole as a treatment for gastroesophageal reflux disease. Clin Exp Gastroenterol. 2010;3:11-6. DOI: 10.2147/ceg.s6355
8. Remes-Troche J.M., Sobrino-Cossio S., Soto-Peres J.C., Teramoto-Matsubara O., Morale-Arambula M., Orozko-Gamiz A., et al. Efficacy, safety, and tolerability of pantoprazole magnesium in the treatment of reflux symptoms in patients with gastroesophageal reflux disease (GERD): a prospective, multicenter, post-marketing observational study. Clin Drug Investig. 2014;34(2):83-93.. DOI: 10.1007/s40261-013-0135-4
9. Morales-Filho J.P., Pedroso M., Quigley E.M.M., PAMES Study Group. Randomised clinical trial: daily pantoprazole magnesium 40 mg vs. esomeprazole 40 mg for gastro-oesophageal reflux disease, assessed by endoscopy and symptoms. Aliment Pharmacol Ther. 2014;39(1):47-56. DOI: 10.1111/apt.12540
10. Dabrowski A., Stabuc D., Lazebnik L. Meta-analysis of the efficacy and safety of pantoprazole in the treatment and symptom relief of patients with gastroesophageal reflux disease — PAN-STAR. Prz Gastroenterol. .2018; 13(1): 6-15. DOI: 10.5114/pg.2018.74556
11. Lopes-Alvarenga J.C., Orr W., Vargas-Romero J.A., Remes-Troche J.M., Morales-Arambula M., Soto-Peres J.C., et al. Relief of night-time symptoms associated with gastroesophageal reflux disease following 4 weeks of treatment with pantoprazole magnesium: The Mexican gastroesophageal reflux disease working group. J Neuro-gastroenterol Motil. 2014;20(1):64-73. DOI: 10.5056/jnm.2014.20.1.64
12. Kindt S., Imschoot J., Tack J. Prevalence of and impact of pantoprazole on nocturnal heartburn and associated sleep complaints in patients with erosive esophagitis. Dis Esophagus. 2011;24( 8):531-7. DOI: 10.1111/j.1442-2050.2011.01189.x
13. Li M.-J., Li Q., Sun M., Liu L.-Q. Comparative effectiveness and acceptability. Od the FDA-licensed proton-pump inhibitors for erosive esophagitis. A PRISMA-compliant network meta-analysis. Medicine. 2017;96(39):e8120. DOI: 10.1097/MO0000000000008120
14. Lechien J.R., Bobin F., Muls V., Eisendrath P., Horoi M., Thill M-P., et al. Gastroesophageal reflux in laryngopharyngeal reflux patients: Clinical features and therapeutic response. Laryngoscope. 2020;130(8):E479-89. DOI: 10.1002/lary.28482
15. Hu Z.-H., Shi A.-M., Hu D.-M., Bao J.-J. Efficacy of proton pump inhibitors for patients with duodenal ulcers: A pairwise and network meta-analysis of randomized controlled trials. Saudi J Gastroenterol. 2017;23(1):11-9. DOI: 10.4103/1319-3767.199117
16. Zhang J., Ge L., Hill M., Liang Y., Xie J., Cui D., et al. Standard-dose proton pump inhibitors in the initial non-eradication treatment of duodenal ulcer: systematic review, network meta-analysis, and cost-effectiveness analysis. Front Pharmacol. 2019;9:1512. DOI: 10.3389/fphar.2018.01512
17. McNicholl A.G., Bordin D.S., Lucendo A., Fadeen-ko G., Castro M., Voynovan I., et al. Combination of bismuth and standard triple therapy eradicates Helicobacter pylori infection in more than 90% of patients. Clin Gastroenterol Hepatol. 2020;18(1):89-98. DOI: 10.1016/j.cgh.2019.03.048
18. Kan L.-D., Chen J., Huang Y.-T., Qin Y., Yu X.-L., Fang H.-M., et al. Evaluation of different proton pump inhibitors combined with bismuth quadruple regimens in Helicobacter pylori eradication. Clin Exp Med. 2020 Nov;20(4):609-14. DOI: 10.1007/s10238-020-00643-2
19. Van Rensburg J., Cheer S. Pantoprazole for the treatment of peptic ulcer bleeding and prevention of rebleeding. Clin Med Insights Gastroenterol. 2012;5:51-60. DOI: 10.4137/CGast.S9893
20. Motiei A., Sebghatolahi V. Efficacy comparison of divided and infusion untravenous pantoprazole methods after endoscopic therapy in patients with acute gastrointestinal bleeding. Adv Biomed Res. 2017;6:120. DOI: 10.4103/abr.abr_59_16
21. Barletta J.F., Buckley M.S., MacLaren R. The SUP-ICU trial: does it confirm or condemn the practice of stress ulcer prophylaxis? Hosp Pharm. 2020;55 (2):96-101. DOI: 10.1177/0018578719867687
22. Granholm A., Marker S., Krag M., Zampieri F.G., Thorsen-Meyer H.-C., Kaas-Hansen B.S., et al. Heterogeneity of treatment effect of prophylactic pantoprazole in adult ICU patients: a post hoc analysis of the SUP-ICU trial. Intensive Care Med. 2020;46(4):717-26. DOI: 10.1007/s00134-019-05903-8
23. Wei P., Zhang Y.-G., Ling L., Tao Z.-Q,. Ji L.-Y,. Bai J., et al. Effects of the short-term application of pantopra-zole combined with aspirin and clopidogrel in the treatment of acute STEMI. Exp Ther Med. 2016;12(5):2861-4. DOI: 10.3892/etm.2016.3693
24. Jensen B.E.S., Hansen J.M., Larsen K.S., Junker A., Lassen J.F., Jensen S.E., et al. Randomized clinical trial: the impact of gastrointestinal risk factor screening and prophylactic proton pump inhibitor therapy in patients receiving dual antiplatelet therapy. Eur J Gastroenterol. 2017;29(10):1118-25. DOI: 10.1097/MEG.0000000000000934
25. Farhat N., Haddad N., Crispo J., Birkett N., VcNair D., Momoli F., et al. Trends in concomitant clopidogrel and proton pump inhibitor treatment among ACS inpatients, 2000-2016. Eur J Clin Pharmacol. 2019;75(2):227-35. DOI: 10.1007/s00228-018-2564-8
26. Moayyedi P., Eikelboom J.W., Bosch J., Conolly S.J., Dyal L., Shestakovska O., et al. Pantoprazole to prevеnt gastroduodenal events in patients receiving rivaroxaban and/or aspirin in a randomized, double blind, placebo-controlled trial. Gastroenterology. 2019;157(2):403-12. DOI: 10.1053/j.gastro.2019.04.041
27. Lee B.E., Kim G.H., Song G.A., Seo J.H., Jeon J.Y., Baek D.H., Kim D.U. Continuos infusion versus intermittent dosing with pantoprazole for gastric endoscopic submucosal dissection. Gut Liver. 2019;13(1):40-7. DOI: 10.5009/gnl18222
28. Jung S.W., Kim S.Y., Chor J.W., Hyun J.J., Jung K.Y., Koo J.S., et al. Standard and double-dose intravenous proton pump inhibitor injections for prevention of bleeding after endoscopic resection. J Gastroenterol Hepatol. 2017;32(4):778-81. DOI: 10.1111/jgh.13597
29. Grinevich V.B., Gubonina I.V., Doshchitsin V.L., Kotovskaya Yu.V., Kravchuk Yu.A., Ped V.I., et al. Management of patients with comorbidity during novel coronavirus (COVID-19) pandemic. 2020. Cardiovascular Therapy and Prevention. 2020;19(4):2630. (In Russ.) DOI:10.15829/1728-8800-2020-2630
30. Moayyedi P., Eikelboom J.W., Bosch J., Conolly S.J., Dyal L., Shestakovska O., et al. Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients recriving rivaroxaban or aspirin. Gastroenterology. 2019;157(3):682-91. DOI: 10.1053/j.gastro.2019.05.056
31. Schneider J.L., Kolitsopoulos F., Corley D.A. Risk of gastric cancer, gastrointestinal cancers and other cancers: a comparison of treatment with pantoprazole and other proton pump inhibitors. Aliment Pharmacol Ther. 2016;43(1):73-82. DOI: 10.1111/apt.13450
32. Kuan Y.Ch., Huang K.W., Lin C.J., Luo J.C., Kao C.H. Short-term proton pump inhibitor use and hepatic encephalopathy risk in patients with decompensated cirrhosis. Clin Med. 2019; 8(8):1108. DOI:10.3390/jcm8081108
33. Brunner G., Athmann C., Schneider A. Long-term, openlabel trial: safety and efficacy of continuous maintenance treatment with pantoprazole for up to 15 years in severe acid-peptic disease. Aliment Pharmacol Ther. 2012;36(1):37-47. DOI: 10.1111/j.1365-2036.2012.05106.x
34. Ying J., Li L.-C., Wu C.-Y., Yu Z.-W., Kan L-D. The status of proton pump inhibitor use: a prescription survey of 45 hospitals in China Rev Esp Enferm Dig. 2019;111(10):738-43. DOI: 10.17235/reed.2019.6155/2019
35. Matuz M., Benko R., Engi Z., Schvab K., Doro P., Viola R., et al. Use of proton pump inhibitors in Hungary: mixed-method study to reveal scale and characteristics. Front Pharmacol. 2020;11:552102. DOI: 10.3389/fphar.2020.552102
Review
For citations:
Sheptulin A.A., Kardasheva S.S., Kurbatova A.A. Current Potential of Pantoprazole in Treatment and Prevention of Gastrointestinal Diseases. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2021;31(1):47-53. (In Russ.) https://doi.org/10.22416/1382-4376-2021-31-1-47-53
Views:
2136
Email this article 
